Assessing a live microbial therapy for the treatment of Insomnia
A Phase I/II Randomised, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of a Live Biotherapeutic Product (SVT-4A1011) in Adults with Clinically Diagnosed Insomnia
Servatus Ltd
50 participants
Mar 28, 2022
Interventional
Conditions
Summary
The aim of this study is to evaluate safety and tolerability of SVT-4A1011 as a treatment for Insomnia together with preliminary efficacy. The treatment consists of selected bacterial species that are naturally found in the digestive tract. They are a research focus for their important role in many conditions related to gut health. Bacteria play an important role in the function of the immune system, digestive health, inflammation and gut/brain axis. Several research studies have identified certain gut bacteria having direct interaction and regulation of key neurotransmitters and pathways associated with sleep including influencing the host circadian rhythm. This study will help determine how safe and effective SVT-4A1011 is as a stand-alone therapy in treating Clinically Diagnosed Insomnia. The hypothesis of this study is that, twice daily consumption of the study drug SVT-4A1011 will result in improved quality of sleep in individuals with clinically diagnosed insomnia.
Eligibility
Inclusion Criteria10
- Male and female Participants aged 18 to 70 years, capable of providing written informed consent and able to attend the study site on up to 4 separate occasions,
- Insomnia Severity Index (ISI) score greater than or equal to 8 with insomnia symptoms for more than 3 times per week and present for longer than 3 months,
- Clinical diagnosis of Insomnia determined by clinical interview conducted by a trained sleep psychologist,
- Females of childbearing potential (FOCBP) must have a negative pregnancy test at the Baseline Visit. While on the study, FOCBP who engage in activity in which conception is possible, must use one of the approved contraceptive options described below:
- a. Hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring),
- b. Intrauterine device (IUD),
- c. Tubal Ligation,
- d. Partner’s Vasectomy, or
- e. Barrier method i.e., male or female condom.
- Male Participants who have not had a vasectomy and who engage in activity in which conception is possible, must use barrier contraception i.e., male condom while on study, or if their partner is FOCBP, the partner can use hormonal contraception, an IUD or have had a tubal ligation.
Exclusion Criteria19
- Sleep apnoea (AHI greater than 10) determined by PSG,
- Medical condition, medication or sleep-related movement disorder that may be causative of the insomnia symptoms,
- Shift-worker working hours between 10pm and 4am,
- History of major psychiatric disorder in the past 12 months, such as severe depression, anxiety or other psychopathologic condition based on self-report or depression scores on the DASS21 greater than or equal to 21 or anxiety scores on the DASS21 greater than or equal to 15, except clinically managed mild depression,
- History of suicide attempt, current suicide ideation or self-harm,
- History of hypersensitivity or severe adverse reaction including but not limited to anaphylaxis to any ingredients in SVT-4A1011,
- Skin sensitivity to adhesive or tape,
- Use of any investigational drug and/or device within 4 weeks of screening or intent to use within the duration of the study,
- History of any infection requiring hospitalisation, parental antimicrobial therapy, or as otherwise judged clinically significant, within the 3 months prior to screening,
- Any prior history of septicaemia or bacteraemia,
- Immunocompromised or those with known or suspected history of immunodeficiency,
- Any condition that, in the opinion of the Study Coordinator or Investigators, contradicts participation in this study or poses an additional risk to the Participant including any known and /or suspected, current or recent history of uncontrolled clinically significant renal, haematological, gastrointestinal, endocrine, metabolic, pulmonary, cardiac, or neurological disease of presence of alarm systems,
- Surgical procedure during the baseline/screening period or for the duration of the study unless deemed by the Study Coordinator to be minor and unlikely to impact on the study,
- A Participant requiring prohibited concomitant medications including prohibited dietary supplements,
- Females who are pregnant or breastfeeding or planning on becoming pregnant for the study period (screening and treatment),
- Excessive caffeine or alcohol use, that in the opinion of the investigator or study delegate, contributes to the participant's insomnia,
- Inability or unwillingness to undergo 2 venepuncture’s (e.g., because of poor tolerability or lack of access to veins),
- Inability or unwillingness to complete the stool collection kits on 2 occasions.
- Positive result on urine drug screen.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The overall study duration consists of a total of 7 weeks consisting of 2 weeks of screening/baseline assessment and 5 weeks of intervention (treatment). Participants will be provided with 3 bottles of either the investigational medicine (SVT-4A1011) or Placebo at Baseline (Day 0) as an oral liquid. Participants will consume 10 mL of SVT-4A1011 or Placebo twice daily, morning and evenings for 35 Days on an empty stomach. Participants will record their adherence to the intervention in a participant diary, along with any adverse events and any concomitant medications taken during the study period. At the end of 35 Days participants will return to the clinic for assessment.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12621001413819